Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

NCT01524575 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped the trial was never opened and then withdrawn permanently

Conditions

Metastatic Pancreatic Cancer
ERCC1

Interventions

DRUG: gemcitabine and oxaliplatin

Sponsor

University of Hawaii